Merck & Co.

Animal Parasiticides Market is Anticipated to Reach USD 15.6 billion, at a CAGR of 5.7% CAGR by 2031 - Report by Transparency Market Research Inc.

Retrieved on: 
Tuesday, December 12, 2023
Merck & Co., Research, Safety, Pig, Urbanization, Boehringer Ingelheim, Bayer, Virbac, Research report, Animal, Parasitism, Merck, Zoonosis, Probiotic, Nanotechnology, Growth, Knowledge, Livestock, Poultry, Cattle, Pet industry, Agriculture, Fine chemical, Elanco

WILMINGTON, Del., Dec. 12, 2023 /PRNewswire/ -- The global animal parasiticides market is estimated to flourish at a CAGR of 5.7% from 2023 to 2031. According to Transparency Market Research, sales of animal parasiticides are slated to total US$ 15.6 billion by the end of the aforementioned period of assessment.

Key Points: 
  • Growing urbanization, rising disposable income, and improved awareness about animal health amplify the demand for effective parasiticides.
  • Spot-on treatments and oral tablets dominate the animal parasiticides market, offering efficient and convenient solutions for parasite control in animals.
  • Food-producing animals, particularly cattle, poultry, and swine, lead the animal parasiticides market due to their extensive agricultural significance.
  • North America leads the animal parasiticides market due to advanced research, stringent regulations, and robust veterinary healthcare infrastructure.

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer

Retrieved on: 
Monday, December 11, 2023
SAN, Business development, Senior, Piers, Patient, Merck & Co., Eli Lilly, Therapy, Recode, BMS, Business, Pharmaceutical industry, Medarex, Genentech

SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.

Key Points: 
  • SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.
  • Piers Ingram, Ph.D., Chief Executive Officer and co-founder of Hummingbird Bioscience said: "We are delighted that Angèle is joining our team.
  • Most recently, she served as Senior Vice President and Head of Business Development at ReCode Therapeutics, where she led business development, corporate development, investor and public relations.
  • I believe Hummingbird Bio's approach to precision medicines and its promising clinical antibody assets will redefine the next generation of precision therapeutics," said Dr. Maki.

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer

Retrieved on: 
Monday, December 11, 2023
SAN, Business development, Senior, Piers, Patient, Merck & Co., Eli Lilly, Therapy, Recode, BMS, Business, Pharmaceutical industry, Medarex, Genentech

SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.

Key Points: 
  • SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.
  • Piers Ingram, Ph.D., Chief Executive Officer and co-founder of Hummingbird Bioscience said: "We are delighted that Angèle is joining our team.
  • Most recently, she served as Senior Vice President and Head of Business Development at ReCode Therapeutics, where she led business development, corporate development, investor and public relations.
  • I believe Hummingbird Bio's approach to precision medicines and its promising clinical antibody assets will redefine the next generation of precision therapeutics," said Dr. Maki.

AMSURG Announces Board of Directors

Retrieved on: 
Thursday, November 30, 2023
Cerberus, Health, Merck & Co., Sale, Acquisition, Atlantic Council, First Solar, UnitedHealth Group, Woman, Council, CFO, Labcorp, PIMCO, Patient, American Banker, Insurance, King, SoftBank Group, Marketing, Merck, Army, Foreign policy, Trustee, Compensated emancipation, RBC Capital Markets, Ares Management, Army Forces Command (Germany), Growth, Hospital, Munich Re, Radiology, Kindred Healthcare, Cerberus Capital Management, Professional Football Compensation Committee, Santa Clara University, Management, Nursing, Pollina

NASHVILLE, Tenn., Nov. 30, 2023 /PRNewswire/ -- AMSURG, a leader in ambulatory surgery center services, announced appointments to the organization's Board of Directors. The announcement comes after a successful emergence as an independent company under new leadership and positioned for growth.

Key Points: 
  • NASHVILLE, Tenn., Nov. 30, 2023 /PRNewswire/ -- AMSURG, a leader in ambulatory surgery center services, announced appointments to the organization's Board of Directors.
  • King has been appointed as chair of the AMSURG Board of Directors, and he will also serve on the Compensation Committee.
  • "I am thrilled to have such seasoned and accomplished professionals serving on the AMSURG Board of Directors," said Jeff Snodgrass, president and CEO of AMSURG.
  • "It is an honor to join the AMSURG Board of Directors," said David King, chair of AMSURG's Board of Directors.

AuraVax Therapeutics Appoints Two Healthcare Veterans to its Board of Directors

Retrieved on: 
Tuesday, November 28, 2023
P&G, IAVI, International Society, Licensure, Research, GM, Therapy, Medical Center, ALS, Sanofi Pasteur, American Academy, Merck, Vaccine, Merck & Co., Antibody, Growth, New business development, Knowledge, Bangladesh Technical Education Board, IGM, Hamilton College, Pharmaceutical industry, Sanofi, Biotechnology, Microbiology, Economics, Medication

HOUSTON, Nov. 28, 2023 /PRNewswire/ -- AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced that Thomas Finn and John Shiver have joined the company's board of directors. They will serve with Laurence Cooper who is the chair of AuraVax's board.

Key Points: 
  • They join AuraVax at an exciting time as our lead product, NanoSTING-001, advances to clinical testing.
  • Finn serves as a Board member of Cincinnati Children's Medical Center and is Chair of their Research Committee.
  • He also serves as a Board member for Eikonoklastes Therapeutics, a Biotech company developing gene therapy for amyotrophic lateral sclerosis.
  • Shiver also serves as a board member of Icosavax Inc and IAVI Boards of Directors.

New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib's Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma

Retrieved on: 
Saturday, November 18, 2023
NDA, Glioma, Safety, TGR, Food, European Medicines Agency, Astrocytoma, Dana–Farber Cancer Institute, Progression-free survival, IDH2, Aes, Clinical trial, EMA, Data, Patient, Abstract, PFS, FDA, INDIGO, Division, Pembrolizumab, Merck, Neoplasm, IDH, IDH1, Growth, Merck & Co., Quality of life, Society, SNO, HIV disease progression rates, Medical imaging, Pharmaceutical industry, Laboratoires Servier

BOSTON, Nov. 18, 2023 /PRNewswire/ -- New data from Servier's clinical development program for vorasidenib in IDH-mutant diffuse glioma, presented at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) in Vancouver, Canada, showed that vorasidenib reduced tumor growth as measured by a blinded independent radiology committee. Additional data from the INDIGO study being presented at SNO include health-related quality of life data, indicating patients receiving vorasidenib experience preservation of quality of life, stable neurocognitive function, and seizure control, as well as translational data demonstrating vorasidenib's efficacy across IDH-mutant diffuse gliomas with various additional mutations.

Key Points: 
  • We are honored and excited at the prospect of ushering in a new era of targeted treatment options for patients living with this devastating disease."
  • The safety lead-in was conducted to determine the recommended combination dose for the recently initiated perioperative phase of the study.
  • In this phase, approximately 60 patients will be randomized to the combination treatment, vorasidenib 40 mg once-daily alone, or no treatment prior to surgery.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

AbbVie to acquire HBM portfolio company ImmunoGen for USD 10.1 billion in cash

Retrieved on: 
Thursday, December 14, 2023
Safety, IMGN, HBM, USD, Merck & Co., NYSE, Merck, ImmunoGen, Acquisition, Patient, ABBV, Novartis, AbbVie, Pharmaceutical industry, Chinook

HBM Healthcare Investments today announced that its portfolio company ImmunoGen (NASDAQ: IMGN) will be acquired by AbbVie (NYSE: ABBV) for USD 10.1 billion in cash.

Key Points: 
  • HBM Healthcare Investments today announced that its portfolio company ImmunoGen (NASDAQ: IMGN) will be acquired by AbbVie (NYSE: ABBV) for USD 10.1 billion in cash.
  • The acquisition price of USD 31.26 per ImmunoGen share represents a premium of around 95 percent to the closing price on November 29, 2023.
  • HBM Healthcare Investments has invested USD 17.5 million in ImmunoGen since May 2023 and holds 1.26 million shares worth USD 39.3 million based on the takeover price.
  • For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at [email protected] .

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, November 9, 2023
Neoplasm, FDA, Research, Recommended maximum intake of alcoholic beverages, AACR, ATM, Food, Pembrolizumab, Endometrial cancer, Conference, Merck, PMV, KRAS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, Poster, Pharmacokinetics, Clinical trial, KOL, Merck Sharp & Dohme Federal Credit Union, Mass, Safety, Patient, Breast, Prostate, Merck & Co., Pharmaceutical industry, Cryptocurrency, G&A

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • We look forward to initiating a registrational Phase 2 study in the first quarter of 2024.”
    Third Quarter 2023 and Recent Corporate Highlights:
    Updated clinical results from the Phase 1 PYNNACLE study evaluating PC14586 were featured in a late-breaking poster at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 12, 2023.
  • A copy of the poster can be found on the PMV corporate website here .
  • General and administrative (G&A) expenses were $18.7 million for the nine months ended September 30, 2023, compared to $18.9 million for the nine months ended September 30, 2022.

AI Revolutionizes HBV Vaccine Development as Global Market Grows at a CAGR of 5.33% - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Technology, Infectious Diseases, Health, Artificial Intelligence, WHO, Bioinformatics, LG Chem, Drug design, Intelligence, Composition, Incidence, Pregnancy, Vaccine, Government, ROW, Prevalence, Indian Immunologicals Limited, GSK plc, Merck, Data science, Mother, Vaccination, Liver cancer, Genomics, Transport, COVAX, COVID-19, Antibody, KM, Microbiology, Machine learning, Biochemistry, Blood, Hepatitis A and B vaccine, Serum, Hepatitis B virus, Public, Sanofi, Hepatitis, Hepatitis B, Immunization, Pediatrics, World Health Organization's response to the COVID-19 pandemic, Compound annual growth rate, HBV, Parent, Cirrhosis, Merck & Co.

The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.

Key Points: 
  • The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.
  • Since the approval of the first HBV vaccine in 1981, significant advancements have occurred in the development of HBV vaccines.
  • The United States leads the global market due to a high demand for the HBV vaccine, driven by ongoing HBV infection threats.
  • The integration of AI in vaccine and drug design is poised to accelerate vaccine development, enhance efficacy, and drive the HBV vaccine market's growth.

ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023

Retrieved on: 
Tuesday, November 7, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ovarian cancer, MSS, Progression-free survival, PROC, ENB, DCR, Merck, Merck & Co., HIV disease progression rates, Poster, SITC, Disease, Clinical trial, Immune system, COVID-19, Risk, Merck Sharp & Dohme Federal Credit Union, Cancer, Pancreatic cancer, ORR, Immunotherapy, Platinum, Part, Safety, Therapy, Patient, Pharmaceutical industry

The results show encouraging objective responses, disease control and extended progression-free survival in patients with platinum resistant/ refractory ovarian cancer (PROC).

Key Points: 
  • The results show encouraging objective responses, disease control and extended progression-free survival in patients with platinum resistant/ refractory ovarian cancer (PROC).
  • Study treatment consisted of an initial 7-day run-in period of ENB-003 monotherapy, followed by repeated 3-week cycles of ENB-003 in combination with KEYTRUDA.
  • In an ongoing multi-center Phase 1/2 clinical trial, early efficacy signals suggest that ENB-003 overcomes resistance to pembrolizumab in heavily pre-treated drug resistant cancer patients.
  • The Phase 2 portion of the ENB-003 + pembrolizumab combination study is expected to start in the first half of 2024.